Objective: to evaluate the effect on weight and body composition of a L112 polyglucosamine-based medical device in a group of overweight and obese subjects.
Criteria: BMI between 25 and 32 kg / m2 (no pregnancy, DCA, shellfish allergy, dystiroidism,
psycho-pathologies, acute diseases)
Duration: 3 months
2 tablets of 750 mg per day (1 before lunch and 1 before dinner)
T0 (DXA + sampling + anthropometry + blood pressure)
T1 after 45 days (anthropometry)
T2 after 90 days (DXA + sampling + anthropometry + blood pressure)